Ecnoglutide and Beinaglutide

ecnoglutide — XW003, Yikexin †; beinaglutide — benaglutide, Yi Shan Tang / Feisumei †, recombinant human GLP-1(7–36) amide

Metabolic & weight

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. Both compounds are approved prescription medicines in China, not research-only compounds. This page covers them together because they are the two GLP-1 peptides developed and approved principally in China and are usually searched for as a pair. Approval in China does not mean approval elsewhere, and neither is authorised in the US, EU, UK, Australia or South Africa.

Summary

Class: Ecnoglutide: long-acting GLP-1 receptor agonist peptide, engineered as a cAMP-pathway-biased agonist with a fatty-acid modification. Beinaglutide: recombinant human GLP-1(7–36) amide — the native human sequence, not an analogue
Mechanism: Both activate the GLP-1 receptor to increase glucose-dependent insulin release, suppress glucagon, slow gastric emptying and reduce appetite; they differ almost entirely in how long they last
Routes studied: Both subcutaneous. Ecnoglutide once weekly; beinaglutide three times daily before meals
Half-life: Ecnoglutide: long, supporting weekly dosing †. Beinaglutide: approximately 11 minutes — essentially that of native GLP-1
Storage: Both refrigerated per their labels; beinaglutide is supplied lyophilised in some presentations and requires reconstitution by the pharmacy or patient per label †
Regulatory status: Both approved in China only. Ecnoglutide approved by NMPA January 2026 for chronic weight management †; beinaglutide approved for type 2 diabetes (2016) and later for weight management †

Doses are as reported in studies or by the community — never recommendations.

1What it is

Beinaglutide is unusual in this library: it is the native human GLP-1 fragment, GLP-1(7–36) amide, produced recombinantly, with no modifications. That means it behaves exactly as the natural hormone does — including being destroyed by DPP-4 within minutes. Its of roughly eleven minutes is why it must be injected three times a day before meals, and why it never spread beyond China, where it was approved for type 2 diabetes in 2016. It is the clearest demonstration in the whole class of why every other GLP-1 drug is modified: the native peptide works, but the dosing schedule is impractical.

Ecnoglutide (XW003) is the opposite end of the design spectrum: a modified long-acting GLP-1 analogue with a fatty-acid chain, developed for once-weekly dosing, and deliberately engineered as a "cAMP-biased" — meaning it favours the cAMP arm of GLP-1 receptor signalling over the arrestin arm, on the theory that this maximises insulin secretion and weight effects while reducing receptor internalisation. China's NMPA approved ecnoglutide injection in January 2026 for chronic weight management †.

Cross-link: semaglutide (#3) for the benchmark in this class; liraglutide, exenatide and dulaglutide for the other approved GLP-1 agonists.

2How it's thought to work

Both act at the same receptor, with the same downstream effects seen across the class:

Pancreas. glucose-dependent insulin secretion increases, glucagon falls — so hypoglycaemia is uncommon with either on its own.

Stomach. gastric emptying slows, increasing satiety. With beinaglutide's pre-meal dosing this effect is deliberately timed to each meal rather than continuous.

Brain. appetite centres in the hypothalamus and brainstem reduce hunger.

Biased signalling (ecnoglutide specifically). GLP-1 receptor activation can proceed through cAMP/protein kinase A or through β-arrestin recruitment and receptor internalisation. Ecnoglutide is described as cAMP-biased. Whether that bias translates into a clinical advantage over non-biased weekly is unproven — it is a design rationale, not a demonstrated benefit.

Duration as the real differentiator. native GLP-1 (beinaglutide) gives sharp pulses tied to meals; the modified analogue gives continuous receptor occupancy. These produce different side-effect patterns and different effects on gastric emptying tolerance over time.

A GLP-1 analogue developed in China and biased towards cAMP signalling at the receptor. Weekly dosing, with weight loss comparable to earlier agonists.Schematic — not to scale

3What the research shows

Ecnoglutide for weight management

A multicentre, randomised, double-blind, placebo-controlled Phase 3 trial in Chinese adults with overweight or obesity reported body weight reductions of roughly 9–13% versus placebo over 48 weeks, varying by dose (published in Lancet Diabetes Endocrinol, 2025). This supported the NMPA approval in January 2026. [2]

Ecnoglutide for type 2 diabetes

Phase 3 work in type 2 diabetes has reported HbA1c reductions consistent with the weekly GLP-1 class †.

Beinaglutide for type 2 diabetes

Phase 3 trials supporting the 2016 Chinese approval reported HbA1c reduction versus comparator with the three-times-daily regimen. The trials are published largely in Chinese-language journals and are less accessible to international readers than the semaglutide or liraglutide programmes; this is a genuine limitation when assessing the evidence, not a criticism of the data.

Graded A/B

Beinaglutide for obesity

Randomised trials and real-world cohorts in Chinese populations have reported weight loss with beinaglutide, generally more modest than with weekly analogues, and a Phase 1 pharmacokinetic and safety study in adults with overweight or obesity has been published in English (2024, Front Pharmacol). Mark the obesity indication status †.

Not gradednone adequate

Head-to-head against semaglutide or tirzepatide

No well-powered head-to-head trials against the leading weekly have been reported for either compound. Comparisons of percentage weight loss across trials run in different populations are unreliable, and Chinese trial populations have lower average BMI than Western obesity trials, which affects percentage figures. Community use: essentially none documented in the sense this library uses the term. Both are prescription products in one country. What does exist, and is worth naming, is grey-market supply of material sold under these names — especially "beinaglutide" — outside China. Nothing published supports that use, identity and purity of such material are unverifiable, and the three-times-daily injection schedule of real beinaglutide is poorly suited to anything self-directed.

4Reported side effects and interactions

Literature-reported

Literature (both). the GLP-1 class profile — nausea, vomiting, diarrhoea, constipation, abdominal pain, reduced appetite, injection-site reactions. Mostly early and dose-related. Beinaglutide's three-times-daily schedule produces more injection-site exposure and, in reports, prominent early nausea tied to each dose.

Serious / class-level. gallbladder disease; pancreatitis (rare, causality debated); delayed gastric emptying with aspiration risk under anaesthesia; lean mass loss alongside fat loss; rodent thyroid C-cell tumour findings that carry a class contraindication in people with a history of medullary thyroid carcinoma or MEN2 in Western labels †. Diabetic retinopathy worsening has been a class signal with rapid glycaemic improvement.

Community-reported

nothing reliable; see the note above about grey-market material sold under these names.

Interactions. increased hypoglycaemia risk with insulin or sulfonylureas; slowed absorption of oral medicines; not for use in pregnancy.

Markers researchers commonly monitor

As for the GLP-1 class generally:

Marker	Why it's watched
HbA1c and fasting glucose	the glycaemic endpoints; also the hypoglycaemia risk check if insulin or a sulfonylurea is also prescribed.
Body weight and waist circumference	the weight-management endpoints.
Body composition (DEXA or bioimpedance) and grip strength	lean-mass loss is a class effect and matters more at the lower baseline BMIs typical of the Chinese trial populations.
Lipase and amylase	checked if abdominal pain occurs.
Liver enzymes and eGFR/creatinine	dehydration from gastrointestinal effects affects kidney function.
Resting heart rate	GLP-1 agonists raise it by a few beats per minute.
Lipid panel	improves with weight loss.
Retinal examination	for anyone with existing diabetic retinopathy, following the class signal on rapid glycaemic improvement.
Postprandial glucose specifically for beinaglutide	a pre-meal short-acting GLP-1 targets the post-meal excursion, so fasting glucose alone understates its effect.

Free for everyone. Safety information is never behind a paywall.

5Formulation and administration context

Ecnoglutide is supplied as a once-weekly injection per its approved Chinese label. Beinaglutide is supplied for three-times-daily subcutaneous injection before meals; some presentations are and require strictly per the label, which is a pharmacy or labelled-instruction step rather than an improvised one. Both are approved products in one jurisdiction, dispensed with a label in Chinese; neither has an English-language approved label at the time of review †. There is no self-preparation guidance here, and unit and concentration conventions differ between products, which is where dosing errors occur.

6Commonly studied alongside

Metformin and other oral antidiabetic agents in the approved indications. Compared with, not combined with: semaglutide (#3), liraglutide, dulaglutide, exenatide, and tirzepatide. Also discussed alongside the other China-developed incretins (mazdutide, a GLP-1/glucagon dual agonist) †.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Neither approved. Not FDA-authorised in any indication
European Union	Neither authorised
United Kingdom	Neither licensed
Australia	Neither approved
South Africa	Neither registered
China	Ecnoglutide: NMPA-approved January 2026 for chronic weight management †. Beinaglutide: NMPA-approved for type 2 diabetes since 2016; weight management indication †
Sport	GLP-1 receptor agonists are not prohibited by WADA as of 2026 †. Note that a substance not approved in the athlete's jurisdiction may still fall under S0

8Open questions

Whether cAMP-biased GLP-1 receptor agonism gives any real clinical advantage over conventional weekly .
How either compound performs against semaglutide or tirzepatide head to head.
Whether percentage weight-loss figures from Chinese trial populations transfer to higher-BMI Western populations.
Whether either sponsor pursues approval outside China.
Long-term cardiovascular and kidney outcome data, which exist for semaglutide and not for these.

9References

1Zhao L et al. (2025). Ecnoglutide in Chinese adults with overweight or obesity: a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet Diabetes Endocrinol. PubMed
2NMPA (2026). Marketing approval announcement for ecnoglutide injection, January 2026. PubMed
3Sciwind Biosciences (2026). Announcement of NMPA approval of ecnoglutide injection for chronic weight management (company disclosure). PubMed
4Zhang Y et al. (2024). Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial. Front Pharmacol. PubMed
5Nauck MA, Meier JJ (2018). Incretin hormones: their role in health and disease. Diabetes Obes Metab — class physiology reference. PubMed · DOI
6Jones B et al. (2018). Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nat Commun — biased-agonism rationale. PubMed · DOI

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

31 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.